Auris Medical Am-111

At Manningham Medical Centre, you can find all the data about Auris Medical Am-111. We have collected data about general practitioners, medical and surgical specialists, dental, pharmacy and more. Please see the links below for the information you need.

Altamira Therapeutics - Inner Ear Therapeutics

https://www.aurismedical.com/programs/inner-ear-therapeutics

AM-125 for the treatment of vertigo is expected to complete its Phase 2 TRAVERS trial in Q2 2022 and to move into Phase 3 in Q4 2022. Keyzilen ® (AM-101) for the treatment of acute inner ear tinnitus and Sonsuvi ® (AM-111) for the treatment of acute inner ear hearing loss have both been evaluated in Phase 3 trials, but will require further clinical testing.

Auris Medical Announces Publication of AM-111 Phase 3

https://www.globenewswire.com/news-release/2019/03/11/1751210/0/en/Auris-Medical-Announces-Publication-of-AM-111-Phase-3-Results-in-Peer-Reviewed-Scientific-Journal.html

In addition Auris Medical has two Phase 3 programs under development: Sonsuvi ® (AM-111) for acute inner ear hearing loss and Keyzilen ® (AM-101) for acute inner ear tinnitus. …

Auris Medical

https://www.aurismedical.com/

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in RNA therapeutics, allergy and viral …

Altamira Therapeutics – Inner Ear Therapeutics - Auris …

https://www.aurismedical.com/science/inner-ear-therapeutics

Betahistine, the active substance of AM-125, is a small molecule drug that acts as a partial histamine H1-receptor agonist and a H3-receptor antagonist. Originally, it was developed …

Auris Medical Announces Publication of AM-111 Phase 3 …

https://www.nasdaq.com/press-release/auris-medical-announces-publication-am-111-phase-3-results-peer-reviewed-scientific

In addition Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute …

Auris Announces FDA Fast Track Designation For AM-111

https://hearingreview.com/inside-hearing/industry-news/auris-announces-fda-fast-track-designation-111

Auris Medical Holding AG, a Swiss biopharmaceutical company dedicated to developing therapeutics to treat inner ear disorders, announced on February 24 that …

Efficacy and Safety of AM-111 as Acute Sudden …

https://clinicaltrials.gov/ct2/show/NCT02809118

Study Description. The primary objective of the trial is the confirmation of the efficacy of AM-111 in the recovery of severe to profound idiopathic sudden sensorineural …

Auris Medical Provides Update on AM-111 Development

https://www.globenewswire.com/news-release/2018/01/04/1283360/0/en/Auris-Medical-Provides-Update-on-AM-111-Development-Program.html

The AM-111 0.4 mg/mL treatment group showed a mean improvement of 42.7 dB vs. 26.8 dB in the placebo group (p=0.0176). The improvement was 37.3 dB in the AM …

Auris Medical AM-111 | Tinnitus Talk Support Forum

https://www.tinnitustalk.com/threads/auris-medical-am-111.728/

Auris Medical announced today positive results from a phase IIb clinical trial with AM-111, its investigational drug for the intratympanic (i.t.) treatment of acute …

Auris Medical's Acute Inner Ear Hearing Loss Candidate …

https://www.genengnews.com/news/auris-medicals-acute-inner-ear-hearing-loss-candidate-fails-phase-iii-trial/

AM-111 is formulated in a biocompatible and fully biodegradable gel and administered in a single-dose intratympanic injection into the middle ear. The drug is designed to work by diffusing...

Need more information about Auris Medical Am-111?

At Manningham Medical Centre, we collected data on more than just Auris Medical Am-111. There is a lot of other useful information. Visit the related pages or our most popular pages. Also check out our Doctors page.